guest ::
| Home > Publications Database > NMDA receptor autoantibodies primarily impair the extrasynaptic compartment. > print |
| Home > Publications Database > NMDA receptor autoantibodies primarily impair the extrasynaptic compartment. > print |
| 001 | 271072 | ||
| 005 | 20240811004459.0 | ||
| 024 | 7 | _ | |a 10.1093/brain/awae163 |2 doi |
| 024 | 7 | _ | |a pmid:38758090 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC11292910 |2 pmc |
| 024 | 7 | _ | |a 0006-8950 |2 ISSN |
| 024 | 7 | _ | |a 1460-2156 |2 ISSN |
| 024 | 7 | _ | |a altmetric:163860701 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-00944 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Jamet, Zoe |b 0 |
| 245 | _ | _ | |a NMDA receptor autoantibodies primarily impair the extrasynaptic compartment. |
| 260 | _ | _ | |a Oxford |c 2024 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1723110187_2209 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Autoantibodies directed against the N-methyl-D-aspartate receptor (NMDAR-Ab) are pathogenic immunoglobulins detected in patients suffering from NMDAR encephalitis. NMDAR-Ab alter the receptor membrane trafficking, synaptic transmission and neuronal network properties, leading to neurological and psychiatric symptoms in patients. Patients often have very little neuronal damage but rapid and massive (treatment-responsive) brain dysfunctions related to an unknown early mechanism of NMDAR-Ab. Our understanding of this early molecular cascade remains surprisingly fragmented. Here, we used a combination of single molecule-based imaging of membrane proteins to unveil the spatiotemporal action of NMDAR-Ab on live hippocampal neurons. We first demonstrate that different clones of NMDAR-Ab primarily affect extrasynaptic (and not synaptic) NMDARs. In the first minutes, NMDAR-Ab increase extrasynaptic NMDAR membrane dynamics, declustering its surface interactome. NMDAR-Ab also rapidly reshuffle all membrane proteins located in the extrasynaptic compartment. Consistent with this alteration of multiple proteins, effects of NMDAR-Ab were not mediated through the sole interaction between the NMDAR and EphB2 receptor. In the long term, NMDAR-Ab reduce the NMDAR synaptic pool by slowing down receptor membrane dynamics in a cross-linking-independent manner. Remarkably, exposing only extrasynaptic NMDARs to NMDAR-Ab was sufficient to produce their full-blown effect on synaptic receptors. Collectively, we demonstrate that NMDAR-Ab initially impair extrasynaptic proteins, then the synaptic ones. These data thus shed new and unsuspected light on the mode of action of NMDAR-Ab and, probably, our understanding of (extra)synaptopathies. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a autoantibody |2 Other |
| 650 | _ | 7 | |a encephalitis |2 Other |
| 650 | _ | 7 | |a extrasynaptic NMDA receptor |2 Other |
| 650 | _ | 7 | |a interactome |2 Other |
| 650 | _ | 7 | |a membrane proteins |2 Other |
| 650 | _ | 7 | |a Receptors, N-Methyl-D-Aspartate |2 NLM Chemicals |
| 650 | _ | 7 | |a Autoantibodies |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptor, EphB2 |0 EC 2.7.10.1 |2 NLM Chemicals |
| 650 | _ | 2 | |a Receptors, N-Methyl-D-Aspartate: immunology |2 MeSH |
| 650 | _ | 2 | |a Receptors, N-Methyl-D-Aspartate: metabolism |2 MeSH |
| 650 | _ | 2 | |a Autoantibodies: immunology |2 MeSH |
| 650 | _ | 2 | |a Autoantibodies: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Hippocampus: metabolism |2 MeSH |
| 650 | _ | 2 | |a Neurons: metabolism |2 MeSH |
| 650 | _ | 2 | |a Rats |2 MeSH |
| 650 | _ | 2 | |a Synapses: metabolism |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Cells, Cultured |2 MeSH |
| 650 | _ | 2 | |a Receptor, EphB2: metabolism |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Anti-N-Methyl-D-Aspartate Receptor Encephalitis: immunology |2 MeSH |
| 700 | 1 | _ | |a Mergaux, Camille |b 1 |
| 700 | 1 | _ | |a Meras, Morgane |b 2 |
| 700 | 1 | _ | |a Bouchet, Delphine |b 3 |
| 700 | 1 | _ | |a Villega, Frédéric |b 4 |
| 700 | 1 | _ | |a Kreye, Jakob |0 P:(DE-2719)2811468 |b 5 |u dzne |
| 700 | 1 | _ | |a Prüss, Harald |0 P:(DE-2719)2810931 |b 6 |u dzne |
| 700 | 1 | _ | |a Groc, Laurent |0 0000-0003-1814-8145 |b 7 |
| 773 | _ | _ | |a 10.1093/brain/awae163 |g Vol. 147, no. 8, p. 2745 - 2760 |0 PERI:(DE-600)1474117-9 |n 8 |p 2745 - 2760 |t Brain |v 147 |y 2024 |x 0006-8950 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/271072/files/DZNE-2024-00944%20SUP.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/271072/files/DZNE-2024-00944.pdf |
| 856 | 4 | _ | |x pdfa |u https://pub.dzne.de/record/271072/files/DZNE-2024-00944%20SUP.pdf?subformat=pdfa |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/271072/files/DZNE-2024-00944.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:271072 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811468 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2810931 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRAIN : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b BRAIN : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-21 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-21 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-2719)1810003 |k AG Prüß |l Autoimmune Encephalopathies |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1810003 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|